SARC-F and other screening tests for sarcopenia
- PMID: 34861669
- DOI: 10.1097/MCO.0000000000000801
SARC-F and other screening tests for sarcopenia
Abstract
Purpose of review: Sarcopenia screening tools can enable clinicians to select individuals for more demanding evaluations, and hence, may facilitate its timely diagnosis and management. The most common recommended screening test is SARC-F, whereas many others are proposed. We aimed to summarize the recent studies and evidence performed on SARC-F and other sarcopenia screening tools.
Recent findings: Meta-analysis studies reported that despite having moderate-high specificity, SARC-F has low-moderate sensitivity to detect sarcopenia, which would cause a significant number of individuals having sarcopenia to be unrecognized. Several recent studies aimed to increase sensitivity and utility of SARC-F as a screening tool by i.e., application of lower cut-offs, adding extra-items, and combining with other screening tests. Some of these approaches increased its screening efficacy significantly. In line with its previous studies, SARC-F showed success to predict adverse outcomes in the latest studies as well. Recently, it has also been suggested as a reasonable screening test for frailty. In addition to the long-standing screening tests i.e., anthropometric measures, Ishii Test and Mini Sarcopenia Risk Assessment (MSRA) Questionnaire; new tests, i.e., Taiwan Risk Score for Sarcopenia, Sarcopenia Scoring Assessment Model (SarSA-Mod) and re-purposed tests, i.e., SARQoL questionnaire and fracture risk assessment tool have been investigated as potential screening tests for sarcopenia. Some of these tests performed as well as or superior to standard SARC-F.
Summary: Screening of sarcopenia is critical for public health given its significant prevalence and adverse outcomes. SARC-F is the most recommended tool for screening but has low-moderate sensitivity. Studies performed recently indicate that its sensitivity can be increased by some attempts and it may be used as a reasonable test to screen frailty as well. Some other tests have also been developed/re-purposed for an efficient screening, needing to be tested for their performance and usability with future studies in different populations and settings.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Similar articles
-
Comparing Mini Sarcopenia Risk Assessment With SARC-F for Screening Sarcopenia in Community-Dwelling Older Adults.J Am Med Dir Assoc. 2019 Jan;20(1):53-57. doi: 10.1016/j.jamda.2018.04.012. Epub 2018 Jun 13. J Am Med Dir Assoc. 2019. PMID: 29909052
-
Validation of the Korean Version of the SARC-F Questionnaire to Assess Sarcopenia: Korean Frailty and Aging Cohort Study.J Am Med Dir Assoc. 2018 Jan;19(1):40-45.e1. doi: 10.1016/j.jamda.2017.07.006. Epub 2017 Aug 31. J Am Med Dir Assoc. 2018. PMID: 28843526
-
Performance of SARC-F in Regard to Sarcopenia Definitions, Muscle Mass and Functional Measures.J Nutr Health Aging. 2018;22(8):898-903. doi: 10.1007/s12603-018-1067-8. J Nutr Health Aging. 2018. PMID: 30272090
-
Reliability and Concurrent Validity of the SARC-F and Its Modified Versions: A Systematic Review and Meta-Analysis.J Am Med Dir Assoc. 2021 Sep;22(9):1864-1876.e16. doi: 10.1016/j.jamda.2021.05.011. Epub 2021 Jun 16. J Am Med Dir Assoc. 2021. PMID: 34144049 Review.
-
Screening Tools for Sarcopenia.In Vivo. 2021 Nov-Dec;35(6):3001-3009. doi: 10.21873/invivo.12595. In Vivo. 2021. PMID: 34697131 Free PMC article. Review.
Cited by
-
The diagnostic performance of Cr/CysC for sarcopenia and its predictive value on clinical outcomes in hospitalized older patients: a prospective cohort study.Eur Geriatr Med. 2024 Feb 23. doi: 10.1007/s41999-024-00948-5. Online ahead of print. Eur Geriatr Med. 2024. PMID: 38393457
-
Comparison of the performance of four screening tools for sarcopenia in patients with chronic liver disease.Int J Nurs Sci. 2023 Dec 31;11(1):3-10. doi: 10.1016/j.ijnss.2023.12.014. eCollection 2024 Jan. Int J Nurs Sci. 2023. PMID: 38352295 Free PMC article.
-
Body Composition in Chronic Liver Disease.Int J Mol Sci. 2024 Jan 12;25(2):964. doi: 10.3390/ijms25020964. Int J Mol Sci. 2024. PMID: 38256036 Free PMC article. Review.
-
Sarcopenia and Tuberculosis: Is There Any Connection?J Pers Med. 2023 Jul 6;13(7):1102. doi: 10.3390/jpm13071102. J Pers Med. 2023. PMID: 37511715 Free PMC article. Review.
-
Old muscle, new tricks: a clinician perspective on sarcopenia and where to next.Curr Opin Neurol. 2023 Oct 1;36(5):441-449. doi: 10.1097/WCO.0000000000001185. Epub 2023 Jul 24. Curr Opin Neurol. 2023. PMID: 37501556 Free PMC article. Review.
References
-
- Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019; 48:16–31.
-
- Springer Nature Switzerland AG, Zazzara M, Penfold R, Onder G. Nicola Veronese, Charlotte Beaudart, Shaun Sabico. The Future of Drugs in Sarcopenia. In the textbook of ‘Sarcopenia’ 2021; 181–208.
-
- Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc 2013; 14:531–532.
-
- Voelker SN, Michalopoulos N, Maier AB, Reijnierse EM. Reliability and concurrent validity of the SARC-F and its modified versions: a systematic review and meta-analysis. J Am Med Dir Assoc 2021; 22:1864–1876.
-
- Lu JL, Ding LY, Xu Q, et al. Screening accuracy of SARC-F for sarcopenia in the elderly: a diagnostic meta-analysis. J Nutr Health Aging 2021; 25:172–182.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
